Date & Time of Session - 10/13/25 - from 12:00 - 1:00 PM

Needs/Overview
Pharmacogenomic (PGx)-driven dosing of chemotherapy can be a powerful way to minimize toxicities and individualize treatment plans for cancer patients. The Clinical Pharmacogenomics Implementation Consortium (CPIC) recommends dose adjustments for actionable polymorphisms, such as those seen in DPYD (dihydropyrimidine dehydrogenase), prior to initiating the chemotherapeutic agents metabolized by these enzymes, fluorouracil and capecitabine. Standard doses of these agents in patients who have diminished metabolic activity of DPYD have been shown to result in more toxicity, discontinuation in treatment, and associated healthcare costs. In April of 2024, the National Comprehensive Cancer Network updated their colon cancer guidelines from not recommending routine DPYD testing prior to fluoropyrimidine therapy, to now recommending that practitioners “consider” DPYD testing prior to fluoropyrimidine therapy. Despite this guideline change, there is still controversy surrounding the role of DPYD testing in this population.

Objectives
Upon completion of this activity, participants will be able to:
1. Describe the role of pharmacogenomics in oncology as it relates to fluoropyrimidines.
2. Recognize the controversy surrounding the implementation of standardized DPYD testing.
3. Apply current guideline recommendations to patients receiving fluoropyrimidine therapy.

Target Audience
Free 1 credit hour of Continuing Education for St Elizabeth Health Care providers, Pharmacists, Residents and Students

Special Services
If you require special assistance to attend this event, please call Deanna Fliehman at (859) 301-6191

Speaker
Emma Finger, PharmD
PGY2 Oncology Pharmacy Resident
St Elizabeth Healthcare - Edgewood, Kentucky

Session date: 
10/13/2025 - 12:00pm EDT to 12/11/2025 - 10:59pm EST
Location: 
St. Elizabeth Healthcare
1 Medical Village Drive
Edgewood, KY 41017
United States
See map: Google Maps
Add to calendar: 
  • 1.00 ACPE

    In support of improving patient care, UK HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC), and the Association of Social Work Boards (ASWB) to provide continuing education for the healthcare team.

    This knowledge-based activity will award 1.00 contact hour(s) (0.100 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

  • 1.00 Participation
    UK Healthcare CECentral certifies this activity for 1.00 hour(s) of participation.
Please login or register to take this course.
Faculty List: 
Speaker(s)

Emma Finger, PharmD

has no relevant financial relationships to disclose at this time.